The expression pattern of β-catenin in mesothelial proliferative lesions and its diagnostic utilities

Diagnostic Cytopathology

Volumn 33, Issue 5, 2005, Pages 320-324

  Dai, Yiran ^a,c   Bedrossian, Carlos W M ^b   Michael, Claire W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Norwegian American Hospital   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

catenin; Mesothelial cells; Mesothelioma; Pleural fluid

Indexed keywords

BETA CATENIN; UVOMORULIN; WNT PROTEIN;

CANCER INVASION; CELL NUCLEUS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPLASM; EFFUSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MALIGNANT TRANSFORMATION; MESOTHELIUM CELL; PLEURA BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ASCITIC FLUID; BETA CATENIN; CELL MEMBRANE; CELL NUCLEUS; CYTOPLASM; EPITHELIUM; HUMANS; MESOTHELIOMA; NEOPLASM INVASIVENESS; PLEURAL EFFUSION, MALIGNANT;

EID: 27744567974     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20281     Document Type: Conference Paper

References (17)

1. Pass HI, Robinson BW, Testa JR, Carbone M. Emerging translational therapies for mesothelioma. Chest 1999;116(Suppl. 6):455S-460S.
2. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24(9):1183-1200.
3. Morin PJ. Beta-catenin signaling and cancer. Bioessays 1999;21(12):1021-1030.
4. Ben-Ze'ev A, Shtutman M, Zhurinsky J. The integration of cell adhesion with gene expression: the role of beta-catenin. Exp Cell Res 2000;261(1):75-82.
5. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001;194(1):59-67.
6. Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 1992;9(2):151-161.
7. Chambers HM, Henderson DW. Test and teach. Number twenty-seven. Diagnosis: malignant pleural mesothelioma. Pathology 1981;13(1):8-9, 159-161.
8. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 1992;9(2):124-140.
9. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol 1998;19(2):131-137.
10. McCaughey WT, Al-Jabi M. Differentiation of serosal hyperplasia and neoplasia in biopsies. Pathol Annu 1986;21Pt 1:271-293.
11. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Palhol 1998;110(3):397-404.
12. Cerrato A, Fulciniti F, Avallone A, Benincasa G, Palombini L, Grieco M. Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol 1998;185(3):267-272.
13. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96(10):5522- 5527.
14. Montgomery E, Torbenson MS, Kaushal M, Fisher C, Abraham SC. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 2002;26(10):1296- 1301.
15. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155(2):527-536.
16. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000;114(4):583-590.
17. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198(1):11-26.